SA100 Debut Overseas Highly Recognized by International Authority Experts

SA100 Completes Its First Overseas Animal Trials with Excellent Results, Demonstrating Superior Performance and Readiness for Global Expansion

1. Product Overview

The SA100 Ultrasonic High-Frequency Integrated Surgical Device, independently developed by Saints Sages Surgical, represents a new generation of dual-energy surgical platforms. It is the first domestically developed dual-channel energy system capable of achieving 7mm advanced hemostasis under ultrasonic technology and 7mm large-vessel sealing under advanced bipolar technology, bridging the gap in high-end surgical energy instruments in China.

Equipped with second-generation Real-Time Tissue Effect (RTTE II) and Multi-Pulse Tissue Sensing Technology (MPTS), the SA100 intelligently adapts energy delivery to tissue characteristics.

Under the ultrasonic module, RTTE II enhances cutting and coagulation precision, improving surgical efficiency and safety.

Under the advanced bipolar module, MPTS monitors tissue impedance at 475,000 times per second, ensuring secure vessel fusion through dynamic energy and pressure coordination.

The SA100 has obtained NMPA Class III registration and is applicable to multiple specialties including gastrointestinal, hepatobiliary, gynecologic, thoracic, and urologic surgery.

2. Overseas Animal Trial and Validation

The SA100 recently completed its first overseas in vivo animal experiment (porcine model), marking an important milestone toward international certification and commercialization.
Throughout multi-site procedures — including vessel and bundle sealing in organs such as the spleen, kidney, uterus, and carotid region — the SA100 demonstrated consistent sealing reliability, minimal thermal spread, and high operational stability.

Performance results indicated:

100% vessel closure success rate across all tested diameters.

Average sealing time of approximately 2 seconds for medium and large vessels.

Maximum surface temperature around 80°C, ensuring minimal collateral tissue damage.

These results validate the SA100’s capability to deliver fast, safe, and precise vessel sealing and cutting, positioning it among the leading integrated energy platforms worldwide.

3. Expert Feedback

During the evaluation, international surgical experts expressed strong recognition for SA100’s innovative performance and user-friendly design:

“Sealing is so reliable! One of the best products I’ve ever used.”

“Minimal lateral thermal damage gives great confidence when working near critical structures.”

“The handle design provides excellent ergonomics and comfort.”

“Easy to use, plug-and-play, and incredibly efficient — it feels like the future of surgery.”

4. Outlook and Vision

The overseas debut of the SA100 marks both a technological achievement and a symbol of China’s high-end medical innovation entering the global market. Saints Sages Surgical will continue to refine the SA100 through broader clinical validations and real-world applications, collaborating with global partners to promote safer, more efficient surgical energy solutions worldwide.

As a company rooted in China with a global perspective, Saints Sages Surgical remains committed to the mission of “Revering Life, Courageous in Innovation.” With professional R&D expertise and clinical collaboration, the company strives to continuously meet surgical needs, empower healthcare professionals, and serve patients around the world.